Multiple Myeloma Clinical Trials

167 studies are recruiting for multiple myeloma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 7

1. Family Study of Lymphoproliferative Disorders

   Blood and lymph node cancers can begin in either the lymphatic tissues (as in the case of lymphoma) or in the bone marrow (as with leukemia and myeloma), and they all are involved with the uncontrolled growth of white blood cells. There are many subtypes of these cancers, e.g., chronic lymphocytic …

   Stage

   Not phased

   Ages

   18 to 100

   Site

   Mayo Clinic, Rochester, Minnesota

   Run by

   Mayo Clinic

   See if you can join NCT00626496 on ClinicalTrials.gov

2. Umbilical Cord Blood Transplantation From Unrelated Donors

   This study is being done to determine how long it takes for the engraftment (recovery of blood cell counts) of umbilical cord stem cells and also how often engraftment of umbilical cord stem cells transplanted from an unrelated donor fails. Another purpose will be to document the rate of disease-fr…

   Stage

   Not phased

   Ages

   0 to 75

   Site

   Wilmot Cancer Institute, Rochester, New York

   Run by

   University of Rochester

   See if you can join NCT03016806 on ClinicalTrials.gov

3. ERd Combination Treatment in Newly Diagnosed Multiple Myeloma

   The purpose of this study is to determine the effects that Elranatamab in combination with Lenalidomide and Dexamethasone has on participants that have been newly diagnosed with Multiple Myeloma.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Miami, Miami, Florida

   Run by

   University of Miami

   See if you can join NCT06997081 on ClinicalTrials.gov

4. Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study

   This clinical trial compares the effectiveness of geriatric assessment (GA) guided interventions to accelerate functional recovery after chimeric antigen receptor T-cell (CAR-T) therapy compared to standard of care (SOC) in patients 60 years and older with B-cell non-Hodgkin lymphoma (NHL) or multi…

   Stage

   Phase 2

   Ages

   60 and older

   Site

   City of Hope Medical Center, Duarte, California

   Run by

   City of Hope Medical Center

   See if you can join NCT06052826 on ClinicalTrials.gov

5. Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

   This research is being done to investigate the safety and effectiveness of Darzalex Faspro (daratumumab and hyaluronidase-fihj) (a monoclonal antibody that targets plasma cells that make antibodies) and whether it can lower donor specific antibodies (DSA) levels to low enough levels to permit patie…

   Stage

   EARLY_Phase 1

   Ages

   18 and older

   Site

   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland

   Run by

   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

   See if you can join NCT06398457 on ClinicalTrials.gov

6. Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment

   This study evaluates immune responses after CAR-T therapy to find out if CAR-T therapy reduces the effectiveness of the vaccines (vaccine immunity) against diseases such as measles, mumps and rubella, among others in patients with multiple myeloma and non-Hodgkin lymphoma.

   Stage

   Not phased

   Ages

   18 and older

   Site

   OHSU Knight Cancer Institute, Portland, Oregon

   Run by

   OHSU Knight Cancer Institute

   See if you can join NCT06784167 on ClinicalTrials.gov

7. A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

   The purpose of this study is to assess the safety, tolerability and preliminary effectiveness of CC-92480 (BMS-986348) in novel therapeutic combinations for the treatment of Relapsed or Refractory Multiple Myeloma (RRMM).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UAB Comprehensive Cancer Center, Birmingham, Alabama

   Locations

   17 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT05372354 on ClinicalTrials.gov

8. IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

   This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without isatuximab, daratumumab or rituximab to evaluate the safety, tolerability and pr…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Valkyrie Clinical Trials, Los Angeles, California

   Locations

   12 in total

   Run by

   Indapta Therapeutics, INC.

   See if you can join NCT06119685 on ClinicalTrials.gov

9. PRO and Wearable Data Insights From Individuals With R/R Multiple Myeloma

   This study will evaluate the feasibility of a digital health coaching program for adults with relapsed or refractory multiple myeloma (R/R MM). One hundred adults with R/R MM will be enrolled at The University of Washington. Individuals who agree to take part in the study and sign an informed conse…

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Washington, Seattle, Washington

   Run by

   Pack Health

   See if you can join NCT05956457 on ClinicalTrials.gov

10. VitD3 Supplementation in Patients With Multiple Myeloma

    The goal of this clinical trial is to evaluate post-transplant immune reconstitution and lymphocyte recovery as well as the 3-year progression-free survival of patients with multiple myeloma in two treatment arms. One arm will receive Maintenance Vitamin D and the other arm will receive no maintena…

    Stage

    EARLY_Phase 1

    Ages

    18 and older

    Site

    Georgia Cancer Center at Augusta University, Augusta, Georgia

    Run by

    Amany Keruakous, MD, MS.

    See if you can join NCT05846880 on ClinicalTrials.gov

11. Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma

    This is a phase 1, multicenter, open-label study evaluating the safety and efficacy of ruxolitinib, steroids and lenalidomide among MM patients who currently show progressive disease using BCMA to test progression.

    Stage

    EARLY_Phase 1

    Ages

    18 and older

    Site

    Berenson Cancer Center, West Hollywood, California

    Run by

    Oncotherapeutics

    See if you can join NCT06209606 on ClinicalTrials.gov

12. Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma with Isatuximab

    This descriptive study aims to evaluate the experience of adults with relapsed or refractory multiple myeloma receiving standard of care isatuximab-irfc through collection of quantitative, qualitative and wearable data. Fifty adults with relapsed or refractory multiple myeloma receiving standard of…

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Washington, Seattle, Washington

    Locations

    2 in total

    Run by

    Pack Health

    See if you can join NCT05053607 on ClinicalTrials.gov

13. Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan

    Patients who receive a chemotherapy called melphalan are at high risk of having nausea and vomiting. A medication called olanzapine has been shown to decrease nausea and vomiting after chemotherapy. A previous research study found the 10 mg dose of olanzapine (combined with 3 standard medications u…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Wellstar MCG, Augusta, Georgia

    Run by

    Augusta University

    See if you can join NCT06588413 on ClinicalTrials.gov

14. A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study

    The is a first clinical study for Oricell Therapeutics Inc. in the United States to evaluate the safety, PK, PD and preliminary efficacy of our anti-GPRC5D cell product (OriCAR-017) in subjects with relapsed/refractory multiple myeloma. RIGEL Study

    Stage

    Phase 1

    Ages

    18 to 75

    Site

    Northside Hospital, Atlanta, Georgia

    Run by

    OriCell Therapeutics Co., Ltd.

    See if you can join NCT06271252 on ClinicalTrials.gov

15. Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma

    All4Cure is partnering with community oncology practices participating in the Quality Cancer Care Alliance (QCCA) and Exigent Research to develop a clinical pathway that standardizes the evaluation, treatment and ongoing management of patients with newly diagnosed multiple myeloma who wish to achie…

    Stage

    Not phased

    Ages

    18 and older

    Site

    All4Cure, Seattle, Washington

    Run by

    All4Cure

    See if you can join NCT06149910 on ClinicalTrials.gov

16. A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients

    This is a phase 1, multicenter, open-label study evaluating the safety and efficacy of ruxolitinib, steroids and lenalidomide among MM patients who currently show progressive disease.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Global Oncology, Inc., Alhambra, California

    Locations

    13 in total

    Run by

    Oncotherapeutics

    See if you can join NCT03110822 on ClinicalTrials.gov

17. Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma

    Multiple myeloma (MM) is the second most common hematologic malignancy in adults. The current standard of care for MM patients fit to undergo high dose conditioning chemotherapy is an autologous HCT (autoHCT). Allogeneic HCT (alloHCT) is the only potentially curative therapy available to patients w…

    Stage

    Not phased

    Ages

    Any age

    Site

    Center for International Blood and Marrow Transplant Research, Minneapolis, Minnesota

    Run by

    Center for International Blood and Marrow Transplant Research

    See if you can join NCT03127761 on ClinicalTrials.gov